These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 37304240)

  • 1. A Th2-score in the tumor microenvironment as a predictive biomarker of response to Bacillus Calmette Guérin in patients with non-muscle invasive bladder carcinoma: A retrospective study.
    Villoldo GM; Pombo MT; Aris M; Chemi J; Mandó P; Nagaraju S; Camean J; Burioni A; Egea D; Amat M; Mellado JL; Mordoh J; Villaronga A; Barrio MM
    Oncol Res; 2023; 31(2):207-220. PubMed ID: 37304240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting response to bacillus Calmette-Guérin (BCG) in patients with carcinoma in situ of the bladder.
    Nunez-Nateras R; Castle EP; Protheroe CA; Stanton ML; Ocal TI; Ferrigni EN; Ochkur SI; Jacobsen EA; Hou YX; Andrews PE; Colby TV; Lee NA; Lee JJ
    Urol Oncol; 2014 Jan; 32(1):45.e23-30. PubMed ID: 24055426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-L1 expression and pattern of immune cells in pre-treatment specimens are associated with disease-free survival for HR-NMIBC undergoing BCG treatment.
    Roumiguié M; Compérat E; Chaltiel L; Nouhaud FX; Verhoest G; Masson-Lecomte A; Colin P; Audenet F; Houédé N; Larré S; Xylinas E; Brunelle S; Piana-Thomassin J; Cotte J; Pignot G; Neuzillet Y; Rouprêt M
    World J Urol; 2021 Nov; 39(11):4055-4065. PubMed ID: 32666225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preoperative sarcopenia and systemic immune-inflammation index can predict response to intravesical Bacillus Calmette-Guerin instillation in patients with non-muscle invasive bladder cancer.
    Liu P; Chen S; Gao X; Liang H; Sun D; Shi B; Zhang Q; Guo H
    Front Immunol; 2022; 13():1032907. PubMed ID: 36225922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of pre- and post-treatment PD-L1 expression in patients with primary high-grade non-muscle-invasive bladder cancer treated with BCG immunotherapy.
    Aydin AM; Baydar DE; Hazir B; Babaoglu B; Bilen CY
    World J Urol; 2020 Oct; 38(10):2537-2545. PubMed ID: 31900581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HER2 positivity predicts BCG unresponsiveness and adaptive immune cell exhaustion in EORTC risk-stratified cohort of bladder cancer.
    Nam W; Chae HK; Jung Y; Kang H; Park M; Choi A; Park JY; Eom DW; Kim SJ
    Front Immunol; 2023; 14():1301510. PubMed ID: 38143745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated T-cell Exhaustion and Urinary Tumor DNA Levels Are Associated with Bacillus Calmette-Guérin Failure in Patients with Non-muscle-invasive Bladder Cancer.
    Strandgaard T; Lindskrog SV; Nordentoft I; Christensen E; Birkenkamp-Demtröder K; Andreasen TG; Lamy P; Kjær A; Ranti D; Wang YA; Bieber C; Prip F; Rasmussen J; Steiniche T; Birkbak N; Sfakianos J; Horowitz A; Jensen JB; Dyrskjøt L
    Eur Urol; 2022 Dec; 82(6):646-656. PubMed ID: 36210217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prognostic value of expressions of STAT3, PD-L1, and PD-L2 in Ta/T1 urothelial carcinoma before and after BCG treatment.
    Civriz AH; Teke K; Akdas EM; Dillioglugil O; Vural C; Yaprak Bayrak B
    Urol Oncol; 2023 Dec; 41(12):486.e1-486.e13. PubMed ID: 37690934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of subsequent non-muscle-invasive bladder cancer treated with intravesical Bacillus Calmette-Guérin after radical nephroureterectomy for upper urinary tract urothelial carcinoma.
    Miyake M; Tatsumi Y; Matsumoto H; Nagao K; Matsuyama H; Inamoto T; Azuma H; Yasumoto H; Shiina H; Fujimoto K;
    BJU Int; 2018 May; 121(5):764-773. PubMed ID: 29281857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical interest of PD-L1 immuno-histochemistry expression as a predictive factor of Bacillus Calmette Guerin (BCG) efficacy in refractory high-risk non-muscle-invasive bladder cancer (NMIBC).
    Delcourt C; Gemival P; Nouhaud FX; Gobet F; Gillibert A; Ferlicot S; Sabourin JC; Irani J; Pfister C
    World J Urol; 2020 Jun; 38(6):1517-1524. PubMed ID: 31486884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preoperative abdominal fat distribution and systemic immune inflammation were associated with response to intravesical Bacillus Calmette-Guerin immunotherapy in patients with non-muscle invasive bladder cancer.
    Ke ZB; Chen H; Chen JY; Cai H; Lin YZ; Sun XL; Huang JB; Zheng QS; Wei Y; Xue XY; Xu N
    Clin Nutr; 2021 Dec; 40(12):5792-5801. PubMed ID: 34775222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic and Predictive Value of Fibroblast Growth Factor Receptor Alterations in High-grade Non-muscle-invasive Bladder Cancer Treated with and Without Bacillus Calmette-Guérin Immunotherapy.
    Mayr R; Eckstein M; Wirtz RM; Santiago-Walker A; Baig M; Sundaram R; Carcione JC; Stoehr R; Hartmann A; Bolenz C; Burger M; Otto W; Erben P; Breyer J
    Eur Urol; 2022 Jun; 81(6):606-614. PubMed ID: 35351346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-infiltrating immune cell subpopulations influence the oncologic outcome after intravesical Bacillus Calmette-Guérin therapy in bladder cancer.
    Pichler R; Fritz J; Zavadil C; Schäfer G; Culig Z; Brunner A
    Oncotarget; 2016 Jun; 7(26):39916-39930. PubMed ID: 27221038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined assessment of peritumoral Th1/Th2 polarization and peripheral immunity as a new biomarker in the prediction of BCG response in patients with high-risk NMIBC.
    Martínez R; Tapia G; De Muga S; Hernández A; Cao MG; Teixidó C; Urrea V; García E; Pedreño-López S; Ibarz L; Blanco J; Clotet B; Cabrera C
    Oncoimmunology; 2019; 8(8):1602460. PubMed ID: 31413912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating the cost-utility of intravesical Bacillus Calmette-Guérin versus radical cystectomy in patients with high-risk non-muscle-invasive bladder cancer in the UK.
    Grabe-Heyne K; Henne C; Odeyemi I; Pöhlmann J; Ahmed W; Pollock RF
    J Med Econ; 2023; 26(1):411-421. PubMed ID: 36897006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single immediate instillation of chemotherapy is associated with decreased recurrence and progression in patients with high-risk non-muscle-invasive bladder cancer who receive adjuvant induction bacillus Calmette-Guérin therapy.
    Fujita N; Hatakeyama S; Momota M; Narita T; Tobisawa Y; Yoneyama T; Yamamoto H; Ito H; Yoneyama T; Hashimoto Y; Yoshikawa K; Ohyama C
    Int J Urol; 2022 Aug; 29(8):867-875. PubMed ID: 35577361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of immunotherapy in bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer.
    Mukherjee N; Svatek RS; Mansour AM
    Urol Oncol; 2018 Mar; 36(3):103-108. PubMed ID: 29429897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Intravesical instillation of bacillus Calmette-Guerin for non-muscle invasive bladder cancer: outcomes of 421 patients in a single center].
    Cai T; Lu J; Lin Z; Lup M; Liang H; Qin Z; Ye Y
    Nan Fang Yi Ke Da Xue Xue Bao; 2023 Mar; 43(3):488-494. PubMed ID: 37087596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunological Hallmarks for Clinical Response to BCG in Bladder Cancer.
    Lim CJ; Nguyen PHD; Wasser M; Kumar P; Lee YH; Nasir NJM; Chua C; Lai L; Hazirah SN; Loh JJH; Khor LY; Yeong J; Lim TKH; Low AWX; Albani S; Chong TW; Chew V
    Front Immunol; 2020; 11():615091. PubMed ID: 33584702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bacillus Calmette-Guérin failure in patients with non-muscle-invasive urothelial carcinoma of the bladder may be due to the urologist's failure to detect urothelial carcinoma of the upper urinary tract and urethra.
    Giannarini G; Birkhäuser FD; Recker F; Thalmann GN; Studer UE
    Eur Urol; 2014 Apr; 65(4):825-31. PubMed ID: 24144432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.